These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16258454)

  • 1. Aging and coagulation.
    Sane DC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):583-4. PubMed ID: 16258454
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel oral anticoagulants and diet: the potential for interaction.
    Kamali F
    Am J Hematol; 2009 Apr; 84(4):260-1. PubMed ID: 19253346
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial.
    Testa L; Van Gaal W; Biondi-Zoccai G; Abbate A; Trotta G; Agostoni P
    Eur Heart J; 2007 Jul; 28(14):1782-3; author reply 1783. PubMed ID: 17478456
    [No Abstract]   [Full Text] [Related]  

  • 4. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
    Wang CX; Ding X; Shuaib A
    Exp Neurol; 2008 Sep; 213(1):171-5. PubMed ID: 18598697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Food-drug interactions.
    Cheng TO
    Int J Cardiol; 2006 Jan; 106(3):392-3. PubMed ID: 16337049
    [No Abstract]   [Full Text] [Related]  

  • 7. A new oral anticoagulant: the 50-year challenge.
    Gustafsson D; Bylund R; Antonsson T; Nilsson I; Nyström JE; Eriksson U; Bredberg U; Teger-Nilsson AC
    Nat Rev Drug Discov; 2004 Aug; 3(8):649-59. PubMed ID: 15286732
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecule of the month. Ximelagatran.
    Drug News Perspect; 2004; 17(1):66. PubMed ID: 14993935
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.
    Carlsson SC; Mattsson C; Eriksson UG; Sarich TC; Wåhlander K; Eliasson A; Karlson BW; Sheth SB; Held P
    Thromb Res; 2005; 115(1-2):9-18. PubMed ID: 15567447
    [No Abstract]   [Full Text] [Related]  

  • 11. [Slope of decrease of coagulation factors during anticoagulant therapy (tioclomarol) (author's transl)].
    Valty J; Dumoulin P; Vergoz D; Rozenstajn L; Ferrer F; Jaillon P
    Therapie; 1980; 35(5):613-8. PubMed ID: 7209858
    [No Abstract]   [Full Text] [Related]  

  • 12. [Behavior of various blood coagulation factors during anticoagulant therapy].
    CIOCIA D; BESOZZI F
    Omnia Med Suppl; 1955; 6(2):165-217. PubMed ID: 13266308
    [No Abstract]   [Full Text] [Related]  

  • 13. Current challenges of anticoagulant treatment.
    Ginghină C; Giuşcă S; Serban M; Popescu BA; Jurcuţ R; Uscăţescu V
    Rom J Intern Med; 2007; 45(3):221-7. PubMed ID: 18333353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
    Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
    Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
    Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
    Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood coagulation: mechanisms of regulation].
    Panteleev MA; Kotova IaN; Tokarev AA; Ataullakhanov FI
    Ter Arkh; 2008; 80(7):88-91. PubMed ID: 18763608
    [No Abstract]   [Full Text] [Related]  

  • 17. [Physiology of blood coagulation and fibrinolysis: biochemistry].
    Preissner KT
    Hamostaseologie; 2008 Dec; 28(5):259-71. PubMed ID: 19132158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modeling of blood coagulation cascade: kinetics of intrinsic and extrinsic pathways in normal and deficient conditions.
    Zhu D
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):637-46. PubMed ID: 17890951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes.
    Belliard A; Mauco G; Bonnet ML; Hauet T; Macchi L
    Cell Mol Biol (Noisy-le-grand); 2008 Dec; 54 Suppl():OL1077-82. PubMed ID: 19149969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The behavior of the blood coagulation system under the influence of 2-ethyl-3,3-diphenyl-propene-(2)-yl-amine].
    Nowicki L
    Arzneimittelforschung; 1965 Mar; 15(3):281-5. PubMed ID: 5897219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.